Clinical Trial Update: The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient

View source ↗

Summary

The clinical trial evaluating the predictive value of TMPRSS2-ERG fusion in high-risk prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Sir Mortimer B. Davis - Jewish General Hospital | Conditions: Prostate Cancer | Status: WITHDRAWN